<HTML>
<HEAD>
<BASE target="_top">
<TITLE>United States Patent: 8183284</TITLE></HEAD>
<!-BUF1=8183284
BUF7=2012
BUF8=33943
BUF9=/1/
BUF51=8
-->
<BODY bgcolor="#FFFFFF">
<A name="top"></A>
<CENTER>
<IMG src="/netaicon/PTO/patfthdr.gif" alt="[US Patent & Trademark Office, Patent Full Text and Image Database]">
<BR>
<TABLE>
<TR><TD align="center">
<A href="/netahtml/PTO/index.html"><IMG src="/netaicon/PTO/home.gif" alt="[Home]" border="0" valign="middle"></A>
<A href="/netahtml/PTO/search-bool.html"><IMG src="/netaicon/PTO/boolean.gif" alt="[Boolean Search]" border="0" valign="middle"></A>
<A href="/netahtml/PTO/search-adv.htm"><IMG border="0" src="/netaicon/PTO/manual.gif" ALT="[Manual Search]" valign="middle"></A>
<A href="/netahtml/PTO/srchnum.htm"><IMG src="/netaicon/PTO/number.gif" alt="[Number Search]" border="0" valign="middle"></A>
<A href="/netahtml/PTO/help/help.htm"><IMG border="0" valign="middle" src="/netaicon/PTO/help.gif" ALT="[Help]"></A>
</TD></TR>
<TR><TD align="center">
   <A  HREF=/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=49&p=1&f=S&l=50&d=PTXT&S1=(aspirin.TI.+OR+aspirin.ABTX.)&Query=+((ttl/aspirin+or+abst/aspirin))><IMG VALIGN=MIDDLE SRC=/netaicon/PTO/hitlist.gif border=0 ALT=[HIT_LIST]></A>
<A  HREF=/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=49&p=2&f=S&l=50&d=PTXT&S1=(aspirin.TI.+OR+aspirin.ABTX.)&Query=+((ttl/aspirin+or+abst/aspirin))><IMG VALIGN=MIDDLE SRC=/netaicon/PTO/nextlist.gif border=0 ALT=[NEXT_LIST]></A>
<A  HREF=/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=48&p=1&f=G&l=50&d=PTXT&S1=(aspirin.TI.+OR+aspirin.ABTX.)&OS=+((ttl/aspirin+or+abst/aspirin))><IMG VALIGN=MIDDLE SRC=/netaicon/PTO/prevdoc.gif border=0 ALT=[PREV_DOC]></A>
<A  HREF=/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=50&p=1&f=G&l=50&d=PTXT&S1=(aspirin.TI.+OR+aspirin.ABTX.)&OS=+((ttl/aspirin+or+abst/aspirin))><IMG VALIGN=MIDDLE SRC=/netaicon/PTO/nextdoc.gif border=0 ALT=[NEXT_DOC]></A>

<A href="#bottom"><IMG src="/netaicon/PTO/bottom.gif" alt="[Bottom]" valign="middle" border="0"></A>
</TD></TR>
   <TR><TD align="center">
   <A href="https://certifiedcopycenter.uspto.gov/other/patft/view.html?backUrl1=http%3A//patft.uspto.gov/netacgi/nph-Parser?Sect1%3DPTO2%26Sect2%3DHITOFF%26u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-adv.htm%26r%3D49%26p%3D1%26f%3DG%26l%3D50%26d%3DPTXT%26S1%3D(aspirin.TI.%252BOR%252Baspirin.ABTX.)%26OS%3D%252B((ttl%2Faspirin%252Bor%252Babst%2Faspirin))&backLabel1=Back%20to%20Document%3A%208183284"><IMG border="0" src="/netaicon/PTO/cart.gif" border="0" valign="middle" alt="[View Shopp
ing Cart]"></A>
   <A href="https://certifiedcopycenter.uspto.gov/other/patft/order.html?docNumber=8183284&backUrl1=http%3A//patft.uspto.gov/netacgi/nph-Parser?Sect1%3DPTO2%26Sect2%3DHITOFF%26u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-adv.htm%26r%3D49%26p%3D1%26f%3DG%26l%3D50%26d%3DPTXT%26S1%3D(aspirin.TI.%252BOR%252Baspirin.ABTX.)%26OS%3D%252B((ttl%2Faspirin%252Bor%252Babst%2Faspirin))&backLabel1=Back%20to%20Document%3A%208183284">
   <IMG border="0" src="/netaicon/PTO/order.gif" valign="middle" alt="[Add to Shopping Cart]"></A>
   </TD></TR>
   <TR><TD align="center">
   <a href=http://pdfpiw.uspto.gov/.piw?Docid=08183284&homeurl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-adv.htm%2526r%3D49%2526p%3D1%2526f%3DG%2526l%3D50%2526d%3DPTXT%2526S1%3D(aspirin.TI.%252BOR%252Baspirin.ABTX.)%2526OS%3D%252B((ttl%2Faspirin%252Bor%252Babst%2Faspirin))%2526RS%3D(TTL%2Faspirin%252BOR%252BABST%2Faspirin)&PageNum=&Rtype=&SectionNum=&idkey=NONE&Input=View+first+page><img src="/netaicon/PTO/image.gif" alt="[Image]" border="0" valign="middle"></A>

   </TD></TR>
</TABLE>
</CENTER>
<TABLE width="100%">
<TR><TD align="left" width="50%">&nbsp;</TD>
<TD align="right" valign="bottom" width="50%"><FONT size="-1">( <STRONG>49</STRONG></FONT> <FONT size=-2>of</FONT> <STRONG><FONT size=-1>291</STRONG> )</FONT></TD></TR></TABLE>
<HR>
   <TABLE width="100%">
   <TR>	<TD align="left" width="50%"><b>United States Patent </b></TD>
   <TD align="right" width="50%"><b>8,183,284</b></TD>
   </TR>
     <TR><TD align="left" width="50%"><b>
             Sprafka, II
, &nbsp; et al.</b>
     </TD>
     <TD align="right" width="50%"> <b>
     May 22, 2012
</b></TD>
     </TR>
     </TABLE>
       <HR>
       <FONT size="+1">Compositions for reducing the incidence of drug induced arrhythmia
</FONT><BR>
       <BR><CENTER><b>Abstract</b></CENTER>
       <p> In accordance with the present invention, novel methods and formulations
     are provided for treating and preventing the incidence of drug-induced
     pro-arrhythmia, including torsades de pointes. The methods and
     formulations comprise a combination of a drug that induces torsade de
     pointes, such as Class III antiarrhythmics, certain antimicrobials,
     antihistamines, antidepressants, antipsychotics, diuretics, with an
     <B><I>aspirin</I></B> and/or a statin. In certain embodiments, the compositions and
     methods for treatment comprise azimilide and <B><I>aspirin</I></B> and/or a statin.
     These compositions may be administered by different routes, including
     orally. In certain embodiments where the antiarrhythmic is azimilide it
     may be administered orally in a dose of about 25 mg to about 300 mg.
</p>
       <HR>
<TABLE width="100%"> <TR> <TH scope="row" valign="top" align="left" width="10%">Inventors:</TH> <TD align="left" width="90%">
 <B>Sprafka, II; Joseph Michael</B> (Loveland, OH)<B>, Goulart-Brum; Jose Mauro</B> (Loveland, OH) </TD> </TR>
<TR> <TH scope="row" valign="top" align="left" width="10%">Assignee:</TH>
<TD align="left" width="90%">

<B>Warner Chilcott Company, LLC</B>
 (Fajardo, 
PR)
<BR>

</TD>
</TR>
       <TR><TH scope="row" valign="top" align="left" width="10%" nowrap>Family ID:
       </TD><TD align="left" width="90%">
       <b>37547445
</b></TD></TR>
       <TR><TH scope="row" valign="top" align="left" width="10%" nowrap>Appl. No.:
       </TH><TD align="left" width="90%">
       <b>11/489,756</b></TD></TR>
       <TR><TH scope="row" valign="top" align="left" width="10%">Filed:
       </TH><TD align="left" width="90%">
       <b>July 20, 2006</b></TD></TR>
     </TABLE>
<HR> <CENTER><b>Prior Publication Data</b></CENTER> <HR> <TABLE width="100%"> <TR><TH scope="col"></TH><TH scope="col"></TH><TD></TD></TR> <TR><TD align="left">
</TD><TH scope='col' align=center><B><U>Document Identifier</U></B></TH><TH scope='col' align=center><B><U>Publication Date</U></B></TH></TR><TR><TD align=center> </TD><TD align=center> US 20070021395 A1</TD><TD align=center>Jan 25, 2007</TD></TR><TR><TD align=center> 
</TD>
</TR> </TABLE>
<HR> <CENTER><b>Related U.S. Patent Documents</b></CENTER> <HR> <TABLE width="100%"> <TR><TH scope="col" width="7%"></TH><TH scope="col"></TH><TH scope="col"></TH> <TH scope="col"></TH><TH scope="col"></TH><TD></TD></TR> <TR><TD align="left">
</TD><TH scope='col' align=center><B><U>Application Number</U></B></TH><TH scope='col' align=center><B><U>Filing Date</U></B></TH><TH scope='col' align=center><B><U>Patent Number</U></B></TH><TH scope='col' align=center><B><U>Issue Date</U></B></TH><TD</TD></TR><TR><TD align=center> </TD><TD align=center>60701555</TD><TD align=center>Jul 22, 2005</TD><TD align=center></TD><TD align=center></TD><TD</TD></TR><TR><TD align=center> 
</TD>
</TR> </TABLE>     <HR>
<p> <TABLE width="100%"> <TR><TD valign="top" align="left" width="30%"><b>Current U.S. Class:</b></TD> <TD valign="top" align="right" width="70%"><b>514/468</b>; 514/471; 514/461 </TD></TR> 
       <TR><TD valign="top" align="left" width="30%"><b>Current CPC Class: </b></TD>
       <TD valign="top" align="right" width="70%">A61K 31/60&nbsp(20130101); A61P 39/00&nbsp(20180101); A61P 9/06&nbsp(20180101); A61P 25/00&nbsp(20180101); A61K 31/366&nbsp(20130101); A61K 45/06&nbsp(20130101); A61K 31/616&nbsp(20130101); A61K 31/496&nbsp(20130101); A61P 29/00&nbsp(20180101); A61K 31/401&nbsp(20130101); A61K 31/22&nbsp(20130101); A61K 31/496&nbsp(20130101); A61K 2300/00&nbsp(20130101); A61K 31/616&nbsp(20130101); A61K 2300/00&nbsp(20130101); A61K 31/22&nbsp(20130101); A61K 2300/00&nbsp(20130101); A61K 31/366&nbsp(20130101); A61K 2300/00&nbsp(20130101); A61K 31/401&nbsp(20130101); A61K 2300/00&nbsp(20130101); A61K 31/60&nbsp(20130101); A61K 2300/00&nbsp(20130101)</TD></TR>
         <TR><TD valign="top" align="left" width="30%"><b>Current International Class: </b></TD>
         <TD valign="top" align="right" width="70%">A01N 43/08&nbsp(20060101); A61K 31/34&nbsp(20060101)</TD></TR>
       <TR><TD valign="top" align="left" width="30%"><b>Field of Search: </b></TD>
       <TD align="right" valign="top" width="70%">
       


 ;514/468,461,471
       </TD></TR>
     </TABLE>
<HR><CENTER><b>References Cited  <A href="/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-adv.htm&r=0&f=S&l=50&d=PALL&Query=ref/8183284">[Referenced By]</A></b></CENTER>       <HR>
       <CENTER><b>U.S. Patent Documents</b></CENTER>
<TABLE width="100%"> <TR><TH scope="col" width="33%"></TH> <TH scope="col" width="33%"></TH> <TH scope="col" width="34%"></TH></TR> <TR> <TD align="left">
<a href="/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN%2F3882228">3882228</a></TD><TD align =left>
May 1975</TD><TD align=left>
Boncey et al.</TD></TR><TR><TD align=left>
<a href="/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN%2F3887700">3887700</a></TD><TD align =left>
June 1975</TD><TD align=left>
Boncey et al.</TD></TR><TR><TD align=left>
<a href="/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN%2F5328909">5328909</a></TD><TD align =left>
July 1994</TD><TD align=left>
Ando et al.</TD></TR><TR><TD align=left>
<a href="/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN%2F5416117">5416117</a></TD><TD align =left>
May 1995</TD><TD align=left>
Ando et al.</TD></TR><TR><TD align=left>
<a href="/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN%2F5422359">5422359</a></TD><TD align =left>
June 1995</TD><TD align=left>
Ando et al.</TD></TR><TR><TD align=left>
<a href="/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN%2F5981555">5981555</a></TD><TD align =left>
November 1999</TD><TD align=left>
Kuhrts et al.</TD></TR><TR><TD align=left>
<a href="/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN%2F6103742">6103742</a></TD><TD align =left>
August 2000</TD><TD align=left>
Ikeda et al.</TD></TR><TR><TD align=left>
<a href="/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN%2F6245797">6245797</a></TD><TD align =left>
June 2001</TD><TD align=left>
Winokur</TD></TR><TR><TD align=left>
<a href="/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN%2F6316487">6316487</a></TD><TD align =left>
November 2001</TD><TD align=left>
Druzgala et al.</TD></TR><TR><TD align=left>
<a href="http://appft.uspto.gov/netacgi/nph-Parser?TERM1=20030119794&Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=0&f=S&l=50" target="_blank">2003/0119794</a></TD><TD align =left>
June 2003</TD><TD align=left>
Bacaner et al.</TD></TR><TR><TD align=left>
<a href="http://appft.uspto.gov/netacgi/nph-Parser?TERM1=20040137054&Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=0&f=S&l=50" target="_blank">2004/0137054</a></TD><TD align =left>
July 2004</TD><TD align=left>
Hager et al.</TD></TR><TR><TD align=left>
<a href="http://appft.uspto.gov/netacgi/nph-Parser?TERM1=20040248820&Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=0&f=S&l=50" target="_blank">2004/0248820</a></TD><TD align =left>
December 2004</TD><TD align=left>
D'Amato</TD></TR><TR><TD align=left>
<a href="http://appft.uspto.gov/netacgi/nph-Parser?TERM1=20050070552&Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=0&f=S&l=50" target="_blank">2005/0070552</a></TD><TD align =left>
March 2005</TD><TD align=left>
Fedida et al.</TD></TR><TR><TD align=left>
<a href="http://appft.uspto.gov/netacgi/nph-Parser?TERM1=20050101565&Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=0&f=S&l=50" target="_blank">2005/0101565</a></TD><TD align =left>
May 2005</TD><TD align=left>
Dasseux</TD></TR><TR><TD align=left>
<a href="http://appft.uspto.gov/netacgi/nph-Parser?TERM1=20050142129&Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=0&f=S&l=50" target="_blank">2005/0142129</a></TD><TD align =left>
June 2005</TD><TD align=left>
Mangano</TD></TR><TR><TD align=left>
<a href="http://appft.uspto.gov/netacgi/nph-Parser?TERM1=20050142180&Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=0&f=S&l=50" target="_blank">2005/0142180</a></TD><TD align =left>
June 2005</TD><TD align=left>
Bisgaier et al.</TD></TR><TR><TD align=left>
<a href="http://appft.uspto.gov/netacgi/nph-Parser?TERM1=20050143354&Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=0&f=S&l=50" target="_blank">2005/0143354</a></TD><TD align =left>
June 2005</TD><TD align=left>
Verbeuren et al.</TD></TR><TR><TD align=left>

</TD>
</TR> </TABLE>
       <CENTER><b>Foreign Patent Documents</b></CENTER>
<TABLE width="100%"> <TR><TD></TD><TH scope="col"></TH> <TD></TD><TH scope="col"></TH> <TD></TD><TH scope="col"></TH></TR> <TR> <TD align="left">
</TD><TD align=left>742544</TD><TD></TD><TD align=left>
Dec 1955</TD><TD></TD><TD align=left>
GB</TD></TR><TR><TD align=left>
</TD><TD align=left>1025862</TD><TD></TD><TD align=left>
Apr 1966</TD><TD></TD><TD align=left>
GB</TD></TR><TR><TD align=left>
</TD><TD align=left>1142757</TD><TD></TD><TD align=left>
Feb 1969</TD><TD></TD><TD align=left>
GB</TD></TR><TR><TD align=left>
</TD><TD align=left>1269181</TD><TD></TD><TD align=left>
Apr 1972</TD><TD></TD><TD align=left>
GB</TD></TR><TR><TD align=left>
</TD><TD align=left>1287475</TD><TD></TD><TD align=left>
Aug 1972</TD><TD></TD><TD align=left>
GB</TD></TR><TR><TD align=left>
</TD><TD align=left>2253348</TD><TD></TD><TD align=left>
Sep 1992</TD><TD></TD><TD align=left>
GB</TD></TR><TR><TD align=left>
</TD><TD align=left>58-126879</TD><TD></TD><TD align=left>
Jul 1983</TD><TD></TD><TD align=left>
JP</TD></TR><TR><TD align=left>
</TD><TD align=left>2002-534379</TD><TD></TD><TD align=left>
Oct 2002</TD><TD></TD><TD align=left>
JP</TD></TR><TR><TD align=left>
</TD><TD align=left>87/05297</TD><TD></TD><TD align=left>
Sep 1987</TD><TD></TD><TD align=left>
WO</TD></TR><TR><TD align=left>
</TD><TD align=left>90/09185</TD><TD></TD><TD align=left>
Aug 1990</TD><TD></TD><TD align=left>
WO</TD></TR><TR><TD align=left>
</TD><TD align=left>00/40232</TD><TD></TD><TD align=left>
Jul 2000</TD><TD></TD><TD align=left>
WO</TD></TR><TR><TD align=left>
</TD><TD align=left>WO 03/086415</TD><TD></TD><TD align=left>
Oct 2003</TD><TD></TD><TD align=left>
WO</TD></TR><TR><TD align=left>
</TD><TD align=left>2005/018635</TD><TD></TD><TD align=left>
Mar 2005</TD><TD></TD><TD align=left>
WO</TD></TR><TR><TD align=left>

</TD>
</TR> </TABLE>
<TABLE width="90%"> <BR> <CENTER><b>Other References</b></CENTER> <TR><TD><align="left"><BR>Page et al, Circulation 107(8):1141-1145, 2003. cited by examiner
.<BR>Khan et al, Novel therapeutics for treatment of long-QT syndrome and torsade de pointes, International Journal of Cardiology vol. 95, Issue 1, May 2004, pp. 1-6. cited by examiner
.<BR>Sra et al, Curr Probl Cardiol (2000) vol. 25, Issue 7, 413-524. cited by examiner
.<BR>Siu et al (The American Journal of Cardiology, vol. 92, Iss. 11 (Dec. 2003) pp. 1343-1345). cited by examiner
.<BR>Kamath et al, European Heart Journal 22(24) (2001) pp. 2233-2242. cited by examiner
.<BR>Aronow, W.S., "Therapy of Older Persons With Ventricular Arrhythmias", Annals of Long-Term Care, vol. 8, issue 8, Aug. 2000. cited by other
.<BR>Baker, K.E. et al., "Left regional cardiac perfusion in vitro with platelet-activating factor, norepinephrine and K+ reveals that ischaemic arrhythmias are caused by independent effects of endogenous `mediators` facilitated by interactions, and
moderated by paradoxical antagonism", British Journal of Pharmacology, 2004, 142, pp. 352-366. cited by other
.<BR>Brode, S.E. et al., "ICD-antiarrythmic drug and ICD-pacemaker interactions," J. Cardiovasc Electrophysiol. Jul. 1997; 8(7):830-42. cited by other
.<BR>Chen, J. et al., "Pravastatin Prevents Arrhythmias Induced by Coronary Artery Ischemia/Reperfusion in Anesthetized Normocholesterolemic Rats", J. Pharmacol Sci., 93, pp. 87-94, 2003. cited by other
.<BR>Faber, T. S. et al., "Drug-induced torsade-de-pointes: Incidence, management and prevention", Drug Safety, vol. 11, No. 6, 1994, pp. 463-476. cited by other
.<BR>Gillis, A.M., "Effects of antiarrhythmic drugs on QT interval dispersion--Relationship to antiarrhythmic action and proarrhythmia", Progress in Cardiovascular Diseases, 2000, vol. 42, No. 5, pp. 385-396. cited by other
.<BR>Gold, M.R. et al., "Cardiac Arrhythmia: Current therapy", Hosp Pract (Minneap). Sep. 1, 1999; 34(9):27-8, 31-2, 35-8. cited by other
.<BR>Gowda, R. M. et al., "Torsade de pointes: the clinical considerations", International Journal of Cardiology, vol. 96, No. 1, Jul. 2004, pp. 1-6. cited by other
.<BR>Mark, L. et al., "The effect of fluvastatin on QT dispersion and lipid levels", Kardiologia Polska, 2001, vol. 55, No. 11, pp. 386-388. cited by other
.<BR>Mitchell, L.B. et al., "Increased QT interval dispersion in patients with amiodarone-associated torsade de pointes ventricular tachycardia", Canadian Journal of Cardiology, vol. 16, No. Supplement F, Sep. 2000, p. 227F. cited by other
.<BR>Nazeer, S. MD, "Torsade de Pointes", http://emedicine.com, Jul. 6, 2005. cited by other
.<BR>Page, R.L. et al., "Asymptomatic or "Silent" Atrial Fibrillation Frequency in Untreated Patients and Patients Receiving Azimilide," Circulation, Mar. 4, 2003, pp. 1141-11145. cited by other
.<BR>Roden, D.M., "Current status of class III antiarrhythmic drug therapy", Am J. Cariol. Aug. 26, 1993;72(6);44B-49B Abstract. cited by other
.<BR>Ruscin, J.M. et al., "Newer Pharmacologic Agents and Their Relevance to Older Adults", Annals of Long-Term Care, vol. 9, issue 10, Oct. 2001. cited by other
.<BR>Tong, K.L. et al., "A Case Series of Drug-Induced Long QT Syndrome and Torsade de Pointes", Singapore Med. J., 2001 vol. 42(12):566-570. cited by other
.<BR>Tse, H.F. et al., "Current Therapeutics: Management of Atrial Fibrillation", Hong Kong Practitioner 19(11) Nov. 1997. cited by other
.<BR>Zalewski, J., "Dofetilide: A New Class III Antiarrhythmic," Center for Continuing Education, The Cleveland Clinic, vol. III, No. IV, Sep./Oct. 2002. cited by other
.<BR>Joynt et al., "Effect of Angiotensin-Converting Enzyme Inhibitors, Beta Blockers, Statins, and Aspirin on C-Reactive Protein Levels in Outpatients With Heart Failure," The American Journal of Cardiology 93:783-85 (2004). cited by other
.<BR>Office Action in Colombian Patent Application No. 08.005.058, issued Jun. 3, 2011, 18 pages. cited by other
.<BR>First Examination Report in Indian Patent Application No. 425/DELNP/2008, issued Apr. 7, 2011, 2 pages. cited by other
.<BR>Camm et al., "Mortality in Patients After a Recent Myocardial Infarction. A Randomized, Placebo-Controlled Trial of Azimilide Using Heart Rate Variability for Risk Stratification," Circulation 109:990-96 (2004). cited by other
.<BR>Lorenz et al., "Do statins influence the prognostic impact of non-sustained ventricular tachycardia after ST-elevation myocardial infarction?" European Heart Journal 26:1078-85 (2005). cited by other
.<BR>Belardinelli et al., "Assessing predictors of drug-induced torsade de pointes", Trends in Pharmacological Sciences, vol. 24, No. 12, pp. 619-625 (Dec. 2003). cited by other
.<BR>Hohnloser et al., "Amiodarone-associated Proarrhythmic Effects, A Review with Special Reference to Torsade de Pointes Tachycardia", Annals of Internal Medicine, vol. 121, No. 7, pp. 529-535 (Oct. 1, 1994). cited by other
.<BR>Wilkerson et al., "Influence of Nonsteroidal Anti-Inflammatory Drugs on Ouabain Toxicity," American Heart Journal, vol. 94, No. 4, pp. 454-459 (1977). cited by other
.<BR>S. Singh, "Internal Cardioverter Defibrillator (ICD) and Antiarrhythmic Drug Interaction", http://www.americanheart.org/presenter, 2 pages, printed Jul. 12, 2005. cited by other
.<BR>The Arrhythmia Service, "Current Treatments", http://www.arrhythmia.org/current.sub.--treatment.html, 4 pages, printed Jul. 14, 2005. cited by other
.<BR>Touboul, "Securite des nouveaux agents anti-arythmiques", Archives Des Maladies du Coeur et Des Vaisseaux, Tome 97, No. 4, pp. 313-316 (Apr. 2005). cited by other
.<BR>Pratt et al., "Cumulative Experience of Azimilide-Associated Torsades de Pointes Ventricular Tachycardia in the 19 Clinical Studies Comprising the Azimilide Database," J. Am. Coll. Cardiol, vol. 48, No. 3, pp. 471-477 (2006). cited by other.
</TD></TR> </TABLE> <BR>
       <i>Primary Examiner:</i> Packard; Benjamin
<BR>
       <i>Attorney, Agent or Firm:</i> <coma>Fitzpatrick, Cella, Harper & Scinto
<BR>
       <HR>
       <CENTER><b><i>Parent Case Text</b></i></CENTER>
       <HR>
       <BR><BR>CROSS REFERENCE TO RELATED APPLICATION
<BR><BR> This invention claims the benefit under 35 USC 119(e) to U.S. Application
     No. 60/701,555, filed Jul. 22, 2005.
         <HR>
<CENTER><b><i>Claims</b></i></CENTER> <HR> <BR><BR>What is claimed is: <BR><BR> 1.  A method for reducing the incidence of azimilide-induced torsades de pointes consisting essentially of administering azimilide and aspirin to a patient having cardiac
arrhythmia.
<BR><BR> 2.  The method of claim 1, wherein the azimilide is administered daily in amounts from about 75 mg to about 300 mg.
<BR><BR> 3.  The method of claim 1, wherein the aspirin is administered daily in amounts from about 80 mg to about 200 mg.
<BR><BR> 4.  The method of claim 2, wherein the azimilide is administered daily in an amount of about 75 mg.
<BR><BR> 5.  The method of claim 2, wherein the azimilide is administered daily in an amount of about 100 mg.
<BR><BR> 6.  The method of claim 2, wherein the azimilide is administered daily in an amount of about 125 mg.
<BR><BR> 7.  A method for reducing the incidence of azimilide-induced torsades de pointes consisting essentially of administering azimilide and a statin to a patient having cardiac arrhythmia.
<BR><BR> 8.  The method of claim 7, wherein the azimilide is administered daily in amounts from about 75 mg to about 300 mg.
<BR><BR> 9.  The method of claim 8, wherein the azimilide is administered daily in an amount of about 75 mg.
<BR><BR> 10.  The method of claim 8, wherein the azimilide is administered daily in an amount of about 100 mg.
<BR><BR> 11.  The method of claim 8, wherein the azimilide is administered daily in an amount of about 125 mg.
<BR><BR> 12.  A method for reducing the incidence of azimilide-induced torsades de pointes consisting essentially of administering azimilide, aspirin, and a statin to a patient having cardiac arrhythmia.
<BR><BR> 13.  The method of claim 12, wherein the azimilide is administered daily in amounts from about 75 mg to about 300 mg.
<BR><BR> 14.  The method of claim 13, wherein the azimilide is administered daily in an amount of about 75 mg.
<BR><BR> 15.  The method of claim 13, wherein the azimilide is administered daily in an amount of about 100 mg.
<BR><BR> 16.  The method of claim 13, wherein the azimilide is administered daily in an amount of about 125 mg.
<BR><BR> 17.  The method of claim 12, wherein the aspirin is administered daily in amounts from about 80 mg to about 200 mg.
<BR><BR> 18.  The method of claim 1, wherein the cardiac arrhythmia is atrial fibrillation.
<BR><BR> 19.  The method of claim 7, wherein the cardiac arrhythmia is atrial fibrillation.
<BR><BR> 20.  The method of claim 12, wherein the cardiac arrhythmia is atrial fibrillation.
<BR><BR> 21.  The method of claim 1, wherein the cardiac arrhythmia is ventricular arrhythmia.
<BR><BR> 22.  The method of claim 7, wherein the cardiac arrhythmia is ventricular arrhythmia.
<BR><BR> 23.  The method of claim 12, wherein the cardiac arrhythmia is ventricular arrhythmia. <HR> <CENTER><b><i>Description</b></i></CENTER> <HR> <BR><BR>FIELD OF THE INVENTION
<BR><BR> This invention provides methods and formulations for treating and preventing the incidence of drug induced pro-arrhythmia.  In certain embodiments the drugs are for the treatment of cardiac arrhythmia and the methods and formulations of the
present invention further reduce the incidence of torsades de pointes.  In certain embodiments the methods and formulations may comprise a combination of a Class III antiarrhythmic with an aspirin and/or statin.
<BR><BR>BACKGROUND OF THE INVENTION
<BR><BR> Ventricular tachycardias (VT) are triggered by electrical or mechanical intervention in the propagation of electric impulses generated at pace-making regions of the heart.  This interference can be initiated by electrolyte disturbance,
myocardial damage by disease, genetic defects, medications or conditions such as prolonged ischemia.  The most common cause of VT is myocardial ischemia and infarction.
<BR><BR> The control of life-threatening arrhythmias and the prevention of sudden cardiac arrhythmia has been a difficult challenge for modem cardiology.  Large-scale, randomized, controlled trials have greatly contributed to our understanding of the
management of life-threatening arrhythmias.  Available treatments for the management of ventricular arrhythmia include antiarrhythmic drugs, implantable cardioverter defibrillators (ICDs) and catheter ablation.  Each therapy provides unique advantages
for selected patients with life-threatening arrhythmias.
<BR><BR> Any drug that prolongs the action potential duration of cardiac cells (as measured by increases in QT interval from the electrocardiogram) may be proarrhythmic.  Antiarrhythmics that prolong the action potential duration of cardiac cells are
among the most effective class of agents to treat arrhythmias however their use carries a considerable risk of torsades de pointes (TdP).  Torsades de pointes is a form of polymorphic ventricular tachycardia that can cause death and results when there is
prolonged QT intervals.  Besides Class III antiarrhythmics, other drugs that are known to have a risk of causing TdP include but are not limited to some Class I, antimicrobials, antihistamines, antipsychotics, etc, Ramesh M. Gowda et al., "Review Torsade
de pointes: the clinical considerations," International Journal of Cardiology, 96 (2004) 1-6.  Thus, anything that reduces the incidence of TdP will reduce pro-arrhythmia in general and improve the safety of otherwise effective drugs.
<BR><BR> Aspirin is often used as an analgesic (against minor pains and aches), antipyretic (against fever), and anti-inflammatory.  It also has an anticoagulant (blood thinning) effect and is used in long-term low-doses to prevent heart attacks. 
Statins are used to slow the progression of atherosclerosis that causes chest pain, heart attacks, strokes, and intermittent claudication in individuals who have or are at risk for atherosclerosis.  The statins play an important role in the primary and
secondary prevention of coronary heart disease and myocardial infarction.  Research continues into other areas where statins appear to have an effect: inflammation, dementia, and neoplasm (tumors).
<BR><BR>SUMMARY OF THE INVENTION
<BR><BR> In accordance with the present invention, novel methods and formulations are provided for treating and preventing the incidence of drug-induced pro-arrhythmia, including torsades de pointes.  The methods and formulations comprise a combination
of a drug that induces torsade de pointes, such as Class III antiarrhythmics, certain antimicrobials, antihistamines, antidepressants, antipsychotics, diuretics, with an aspirin and/or a statin.  In certain embodiments, the compositions and methods for
treatment comprise azimilide and aspirin and/or a statin.  These compositions may be administered by different routes, including orally.  In certain embodiments where the antiarrhythmic is azimilide it may be administered orally in a dose of about 25 mg
to about 300 mg. <BR><BR>DETAILED DESCRIPTION OF THE INVENTION
<BR><BR> Aspirin or acetylsalicylic acid is a drug in the family of salicylates.
<BR><BR> The term "statin" refers to a class of lipid-lowering drugs that reduce serum cholesterol levels by inhibition of HMG-CoA reductase.  Non-limiting examples of statins useful herein include the following: atorvastatin, fluvastatin, lovastatin,
pravastatin, rosuvastatin, simvastatin and cerivastatin.
<BR><BR> The terms "antiarrhythmic agent" and "antiarrhythmic drug," as used herein, include any pharmaceutically active form of a Class I or Class III antiarrhythmic including, but not limited to, acids, salts, esters, polymorphs, solvates, and
derivatives thereof.  Non-limiting examples of antiarrhythmic drugs useful herein include the following: azimilide, sotalol (including combinations of d,1-sotalol, i.e., racemic sotalol), amiodarone, dofetilide, cibenzoline, and bunafitidine.  Although
any form (e.g., salt, base or amide form) may be used, a salt form is preferred with azimilide, sotalol and amiodarone.  In one embodiment the active agent herein is azimilide dihydrochloride.
<BR><BR> A "pharmaceutically-acceptable salt" is a cationic salt formed at any acidic (e.g., hydroxamic or carboxylic acid) group, or an anionic salt formed at any basic (e.g., amino) group.  Many such salts are known in the art, as described in WO
87/05297, by Johnston et al., published Sept.  11, 1987.  Preferred cationic salts include the alkali metal salts (such as sodium and potassium), and alkaline earth metal salts (such as magnesium and calcium) and organic salts.  Preferred anionic salts
include the halides (such as chloride salts), sulfonates, carboxylates, phosphates, and the like.
<BR><BR> Agents that cause proarrhythmia (proarrhythmic agents) include but are not limited to disopyramide, procainamide, n-acetyl-procainamide, quinidine, beperdil, mexiletine, propafenone, flecainide, amiodarone, bretylium, sotalol, ibutilide,
dofetilide, azimilide, aprindine, ajmaline, almokalant, mibefradil, clofilium, semantilide, erythromycin, clarithromycin, Azithromycin, ampicillin, levofloxacin, moxifloxacin, sparfloxacin, gatifloxacin, grepafloxacin, trimethoprim-sulfamethoxazole,
troleandomycin, pentamidine, quinine, foscarnet, fluconazole, itraconazole, ketoconazole, chloroquine, halofantrine, mefloquine, amantadine, spiramycin, astemizole, diphenhydramine, terfenadine, ebastine, hydroxyzine, doxepin, fluoxetine, desipramine,
imipramine, clomipramine, paroxetine, sertralilne, venlafaxine, citalopram, ketanserin, chlorpromazine, prochlorperazine, trifluoperazine, fluphenazine, felbamate, haloperidol, droperidol, mesoridazine, pimozide, quetiapine, risperidone, thioridazine,
ziprasidone, lithium, chloral hydrate, pericycline, sertindole, sultopride, zimeldine, maprotiline, felbamate, fosphenytoin, sevoflurane, bepridil, lipoflazine, prenylamine, intracoronary papaverine, isradipine, nicardipine, moexipril/hydrochlorthiazide,
arsenic trioxide, tamoxifen, probucol, sumatriptan, zolmitriptan, naratriptan, indapamide thiazide, furosemide, cisapride, metoclopramide, domperidone, erythromycin, arsenic trioxide, tizanidine, tacrolimus, salmeterol, levomethadyl, pinacidil,
cromakalin, aconitine, veratridine, batrachotoxin, anthopleurin A, ketanserin, vincamine, terodiline, budipine, cesium chloride, tiapride, levomethadyl acetate, cocaine, organophosphorus compounds.
<BR><BR> The amount of antiarrhythmic agent contained in the oral dosage forms of the present invention will depend on the particular antiarrhythmic agent selected and the dosing schedule upon which the antiarrhythmic is dosed to the patient.  One
embodiment of the invention comprises a method for treating atrial fibrillation in a mammal in need thereof comprising orally administering to said mammal a solid oral dosage form comprising a unit dose of a pharmaceutical composition comprising a
antiarrhythmic or a pharmaceutically acceptable acid, salt, ester, solvate, or polymorph thereof and from about 80 mg to about 200 mg of an aspirin or from about 1 mg to about 200 mg of a statin.  In one embodiment of the invention a patient is
administered from about 75 mg to about 300 mg of azimilide in combination with both an aspirin and a statin.
<BR><BR> The instant formulations may be separate dosage formulations of the pro-arrhythmic agent and aspirin and/or stain administered concurrently (at the same time) or at different staggered times (sequentially) or the combination comprising an
antiarrhythmic in combination with an aspirin and/or statin may be in a single pharmaceutical dosage formulation.  The instant invention is understood to include all these options.
<BR><BR> The daily dosage amount of the pro-arrhythmic agent are intended to be the same or similar to those amounts which are employed for the treatment of the particular disorder and that are described in either the labels of the FDA approved drugs
(for example amiodorone, dofetilide, sotolol droperidol, levomethadyl, spafloxacin, thioridazine, cisapride) or in published papers on the drugs.  In certain embodiments the daily dosage of dofetilide is about 125 mg to 500 mg and the daily dosage of
amiodorone is from about 400 to about 1600 mg.  In one embodiment the daily dosage of azimilide is about 50 mg to about 150 mg.
<BR><BR> The daily dosage amount of the aspirin or statins are intended to be the same or similar to those amounts which are employed for inflammation or anti-hypercholesterolemic treatment, respectively, and which are described in the Physicians' Desk
Reference.  In one embodiment the oral dosage amount of a statin is from about 1 to 200 mg/day, preferably from about 5 to 160 mg/day.  However, amounts vary depending on the potency of the statin as well as other factors.  The Statin may be administered
from 1 to 4 times per day, preferably once per day.  As examples, simvastatin may be selected from 5 mg, 10 mg, 20 mg, 40 mg, 80 mg and 160 mg; lovastatin, 10 mg, 20 mg, 40 mg, and 80 mg; fluvastatin, 20 mg, 40 mg, and 80 mg; pravastatin, 10 mg, 20 mg,
and 40 mg; and atorvastatin, 10 mg, 20 mg, and 40 mg.
<BR><BR> The pharmaceutical compositions of the present invention may further comprise one or more pharmaceutically-acceptable excipients.  The term "pharmaceutically-acceptable excipients," as used herein, means any physiologically inert,
pharmacologically inactive material known to one skilled in the art, which is compatible with the physical and chemical characteristics of the active ingredient, including but not limited to the antiarrhythmic, aspirin or statin. 
Pharmaceutically-acceptable excipients include, but are not limited to, polymers, resins, plasticizers, fillers, lubricants, diluents, binders, disintegrants, solvents, co-solvents, surfactants, preservatives, sweetening agents, flavoring agents,
pharmaceutical grade dyes or pigments, and viscosity agents.
<BR><BR> The present invention also encompasses the use of an agent that causes pro-arrhythmia for the preparation of a medicament for the combined use with an aspirin or statin for the treatment or prevention of a disorder, such as cardiac arrhythmia,
with reduced incidence of TdP; and the use of an aspirin and/or statin for the preparation of a medicament for the combined use with an agent for the treatment or prevention of a disorder, such as cardiac arrhythmia, with reduced incidence of TdP.  The
medicament or pharmaceutical combination comprised of the agent that may cause pro-arrhythmia and aspirin and/or statin may also be prepared with one or more additional active agents or excipients.  The formulations, method and medicaments of the present
invention may be used with other treatment regimens.  In one embodiment, a medicament comprising azimilide and aspirin and/or statin may be administered to a person with an ICD.
<BR><BR> Flavoring agents and dyes and pigments among those useful herein include those described in Handbook of Pharmaceutical Excipients (4th ed., Pharmaceutical Press 2003).
<BR><BR> Suitable co-solvents include, but are not limited to, ethanol, isopropanol, and acetone.
<BR><BR> Suitable surfactants include, but are not limited to, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene monoalkyl ethers, sucrose monoesters, sodium lauryl sulfate, Tween 80.RTM., and lanolin esters and ethers.
<BR><BR> Suitable preservatives include, but are not limited to, phenol, alkyl esters of parahydroxybenzoic acid, benzoic acid and the salts thereof, boric acid and the salts thereof, sorbic acid and the salts thereof, chlorbutanol, benzyl alcohol,
thimerosal, phenylmercuric acetate and nitrate, nitromersol, benzalkonium chloride, cetylpyridinium chloride, methyl paraben, and propyl paraben.
<BR><BR> Suitable fillers include, but are not limited to, starch, lactose, sucrose, maltodextrin, and microcrystalline cellulose.
<BR><BR> Suitable plasticizers include, but are not limited to, triethyl citrate, polyethylene glycol, propylene glycol, dibutyl phthalate, castor oil, acetylated monoglycerides, and triacetin.
<BR><BR> Suitable polymers include, but are not limited to, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, and ethylcellulose.
<BR><BR> Suitable lubricants include, but are not limited to, magnesium stearate, stearic acid, and talc.
<BR><BR> Kits
<BR><BR> The kits of the present invention are particularly useful for administering one or more unit doses of a solid oral dosage form comprising a pharmaceutical composition of the invention comprising an antiarrhythmic agent and an aspirin and/or
statin and an appropriate continuous dosing schedule.  Such kits comprise one or more unit doses of an antiarrhythmic agent and an aspirin and/or statin and a means for facilitating compliance with methods of this invention.  In one embodiment, a kit of
the present invention is useful for administering a unit dose of a pharmaceutical composition of the present invention according to a continuous dosing schedule.  The term "continuous," as used herein, means at regular specified intervals.  For example,
a continuous frequency of once a month means that the active is given one day each month for an unspecified period of time or for as long as treatment is necessary.
<BR><BR> The kits of the invention provide a convenient and effective means for assuring that the subject to be treated takes the appropriate active in the correct dosage in the correct manner.  The compliance means of such kits includes any means that
facilitates administering the actives according to a method of this invention.  Such compliance means includes instructions, packaging, and dispensing means, and combinations thereof.  The kits can also comprise a means for aiding the memory, including
but not limited to a listing of the days of the week, numbering, illustrations, arrows, Braille, calendar stickers, reminder cards, or other means specifically selected by the patient.
<BR><BR> The following are non-limiting examples of embodiments of the present invention.
<BR><BR>Example 1
<BR><BR> Azimilide Dihydrochloride Film-Coated Tablets, 75 mg and 125 mg are as follows:
<BR><BR> TABLE-US-00001 Unit Quantity Unit Quantity Ingredient (mg/tablet) (mg/tablet) Core Tablet 75 mg 125 mg Azimilide dihydrochloride 75.0 125.0 Lactose monohydrate NF 359.2 319.1 Microcrystalline cellulose NF 133.7 118.7 Crospovidone NF 18.0 18.0
Talc NF 7.5 12.0 Magnesium stearate NF 6.6 6.6 Colloidal silicon dioxide NF 0.0 0.6 Subtotal 600 mg 600 mg Film Coating Dri-Klear 14.18 14.200 Chroma-Tone White (DDB-7536W) 3.82 3.650 Ferric oxide red, NF 0.175 Subtotal 18 mg 18 mg Target Total Tablet
Weight = 618 mg
<BR><BR>Example 2
<BR><BR> Clinical trials are conducted where 5375 patients receive oral doses of azimilide.  Patients are administered azimilide using a 3-day, twice daily loading regimen of 150-250 mg/day followed by a daily maintenance regimen (75-125 mg/day) of 1/2
of the loading dose, or are given daily azimilide (75, 100 or 125 mg/day) without a loading regimen.  Overall about 75% of the patients are men and about 25% are women.  Two cases of TdP are found in placebo-assigned patients and 54 azimilide-associated
cases of TdP.  Lack of aspirin use or lack of statin use is more frequent in azimilide patients with TdP.  A total of 1191 (22%) patients (243 [16%] females and 948 [25%] males) are taking statins and aspirin as concomitant medication.  Among the 54
patients (30 females and 24 males) who experienced TdP, 35% are on aspirin, 20% are on statins and only 11% are taking both a statin and aspirin as concomitant medication.
<BR><BR> All documents cited in the Detailed Description of the Invention are, in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present
invention.  To the extent that any meaning or definition of a term in this written document conflicts with any meaning or definition of the term in a document incorporated by reference, the meaning or definition assigned to the term in this written
document shall govern.
<BR><BR> While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of
the invention.  It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.
<BR><BR><CENTER><b>* * * * *</b></CENTER>
<HR>
   <CENTER>
   <a href=http://pdfpiw.uspto.gov/.piw?Docid=08183284&homeurl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-adv.htm%2526r%3D49%2526p%3D1%2526f%3DG%2526l%3D50%2526d%3DPTXT%2526S1%3D(aspirin.TI.%252BOR%252Baspirin.ABTX.)%2526OS%3D%252B((ttl%2Faspirin%252Bor%252Babst%2Faspirin))%2526RS%3D(TTL%2Faspirin%252BOR%252BABST%2Faspirin)&PageNum=&Rtype=&SectionNum=&idkey=NONE&Input=View+first+page><img src="/netaicon/PTO/image.gif" alt="[Image]" border="0" valign="middle"></A>
   <TABLE>
   <TR><TD align="center"><A href="https://certifiedcopycenter.uspto.gov/other/patft/view.html?backUrl1=http%3A//patft.uspto.gov/netacgi/nph-Parser?Sect1%3DPTO2%26Sect2%3DHITOFF%26u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-adv.htm%26r%3D49%26p%3D1%26f%3DG%26l%3D50%26d%3DPTXT%26S1%3D(aspirin.TI.%252BOR%252Baspirin.ABTX.)%26OS%3D%252B((ttl%2Faspirin%252Bor%252Babst%2Faspirin))&backLabel1=Back%20to%20Document%3A%208183284"><IMG border="0" src="/netaicon/PTO/cart.gif" border="0" valign="m
iddle" alt="[View Shopping Cart]"></A>
   <A href="https://certifiedcopycenter.uspto.gov/other/patft/order.html?docNumber=8183284&backUrl1=http%3A//patft.uspto.gov/netacgi/nph-Parser?Sect1%3DPTO2%26Sect2%3DHITOFF%26u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-adv.htm%26r%3D49%26p%3D1%26f%3DG%26l%3D50%26d%3DPTXT%26S1%3D(aspirin.TI.%252BOR%252Baspirin.ABTX.)%26OS%3D%252B((ttl%2Faspirin%252Bor%252Babst%2Faspirin))&backLabel1=Back%20to%20Document%3A%208183284">
   <IMG border="0" src="/netaicon/PTO/order.gif" valign="middle" alt="[Add to Shopping Cart]"></A>
   </TD></TR>
   <TR><TD align="center">
     <A  HREF=/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=49&p=1&f=S&l=50&d=PTXT&S1=(aspirin.TI.+OR+aspirin.ABTX.)&Query=+((ttl/aspirin+or+abst/aspirin))><IMG VALIGN=MIDDLE SRC=/netaicon/PTO/hitlist.gif border=0 ALT=[HIT_LIST]></A>
<A  HREF=/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=49&p=2&f=S&l=50&d=PTXT&S1=(aspirin.TI.+OR+aspirin.ABTX.)&Query=+((ttl/aspirin+or+abst/aspirin))><IMG VALIGN=MIDDLE SRC=/netaicon/PTO/nextlist.gif border=0 ALT=[NEXT_LIST]></A>
<A  HREF=/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=48&p=1&f=G&l=50&d=PTXT&S1=(aspirin.TI.+OR+aspirin.ABTX.)&OS=+((ttl/aspirin+or+abst/aspirin))><IMG VALIGN=MIDDLE SRC=/netaicon/PTO/prevdoc.gif border=0 ALT=[PREV_DOC]></A>
<A  HREF=/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=50&p=1&f=G&l=50&d=PTXT&S1=(aspirin.TI.+OR+aspirin.ABTX.)&OS=+((ttl/aspirin+or+abst/aspirin))><IMG VALIGN=MIDDLE SRC=/netaicon/PTO/nextdoc.gif border=0 ALT=[NEXT_DOC]></A>

   <A href="#top"><IMG valign="middle" src="/netaicon/PTO/top.gif" border="0" alt="[Top]"></A>
   </TD></TR>
   </TABLE>
   <A name="bottom"></A>
   <A href="/netahtml/PTO/index.html"><IMG src="/netaicon/PTO/home.gif" alt="[Home]" border="0" valign="middle"></A>
   <A href="/netahtml/PTO/search-bool.html"><IMG src="/netaicon/PTO/boolean.gif" alt="[Boolean Search]" border="0" valign="middle"></A>
   <A href="/netahtml/PTO/search-adv.htm"><IMG border="0" src="/netaicon/PTO/manual.gif" alt="[Manual Search]" valign="middle"></A>
   <A href="/netahtml/PTO/srchnum.htm"><IMG src="/netaicon/PTO/number.gif" alt="[Number Search]" border="0" valign="middle"></A>
   <A href="/netahtml/PTO/help/help.htm"><IMG border="0" src="/netaicon/PTO/help.gif" alt="[Help]" valign="middle"></A>
   </CENTER>
</BODY>
</HTML>